169 related articles for article (PubMed ID: 12375010)
1. Sequencing hormonal ablation and radiotherapy in prostate cancer: a molecular and therapeutic prespective (Review).
Hill B; Kyprianou N
Oncol Rep; 2002; 9(6):1151-6. PubMed ID: 12375010
[TBL] [Abstract][Full Text] [Related]
2. Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction.
Cuellar DC; Rhee J; Kyprianou N
Anticancer Res; 2002; 22(3):1673-9. PubMed ID: 12168853
[TBL] [Abstract][Full Text] [Related]
3. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
4. Treatment options in androgen-independent prostate cancer.
Lara PN; Meyers FJ
Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
[TBL] [Abstract][Full Text] [Related]
5. Tumor-targeted apoptosis by a novel spermine analogue, 1,12-diaziridinyl-4,9-diazadodecane, results in therapeutic efficacy and enhanced radiosensitivity of human prostate cancer.
Eiseman JL; Rogers FA; Guo Y; Kauffman J; Sentz DL; Klinger MF; Callery PS; Kyprianou N
Cancer Res; 1998 Nov; 58(21):4864-70. PubMed ID: 9809992
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis and other mechanisms in androgen ablation treatment and androgen independent progression of prostate cancer: a review.
Westin P; Bergh A
Cancer Detect Prev; 1998; 22(5):476-84. PubMed ID: 9727630
[TBL] [Abstract][Full Text] [Related]
7. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
8. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer.
Denmeade SR; Lin XS; Isaacs JT
Prostate; 1996 Apr; 28(4):251-65. PubMed ID: 8602401
[TBL] [Abstract][Full Text] [Related]
9. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
[TBL] [Abstract][Full Text] [Related]
10. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
[TBL] [Abstract][Full Text] [Related]
11. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis.
Aranha O; Grignon R; Fernandes N; McDonnell TJ; Wood DP; Sarkar FH
Int J Oncol; 2003 Apr; 22(4):787-94. PubMed ID: 12632069
[TBL] [Abstract][Full Text] [Related]
12. [Indications of the association of radiotherapy and hormonal treatment in prostate cancer].
Bolla M; Maingon P; Fourneret P; Artignan X; Descotes JL
Cancer Radiother; 2005 Nov; 9(6-7):394-8. PubMed ID: 16226044
[TBL] [Abstract][Full Text] [Related]
13. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
14. Biochemical response after 3-d conformal radiotherapy of localized prostate cancer to a total dose of 66 gy 4-year results.
Wachter-Gerstner N; Wachter S; Goldner G; Nechvile E; Pötter R
Strahlenther Onkol; 2002 Oct; 178(10):542-7. PubMed ID: 12386785
[TBL] [Abstract][Full Text] [Related]
15. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms.
Shankar S; Singh TR; Srivastava RK
Prostate; 2004 Sep; 61(1):35-49. PubMed ID: 15287092
[TBL] [Abstract][Full Text] [Related]
16. Radiation-induced apoptosis: predictive and therapeutic significance in radiotherapy of prostate cancer (review).
Szostak MJ; Kyprianou N
Oncol Rep; 2000; 7(4):699-706. PubMed ID: 10854529
[TBL] [Abstract][Full Text] [Related]
17. Secondary hormonal therapy for advanced prostate cancer.
Lam JS; Leppert JT; Vemulapalli SN; Shvarts O; Belldegrun AS
J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
[TBL] [Abstract][Full Text] [Related]
18. Failure after primary radiation or surgery for prostate cancer: differences in response to androgen ablation.
Swanson GP; Riggs M; Earle J
J Urol; 2004 Aug; 172(2):525-8. PubMed ID: 15247720
[TBL] [Abstract][Full Text] [Related]
19. A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model.
Saleem M; Kweon MH; Yun JM; Adhami VM; Khan N; Syed DN; Mukhtar H
Cancer Res; 2005 Dec; 65(23):11203-13. PubMed ID: 16322271
[TBL] [Abstract][Full Text] [Related]
20. Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer.
Wang G; Sadar MD
J Cell Biochem; 2006 May; 98(1):36-53. PubMed ID: 16440300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]